OptImms: Optimising immunisation schedules in Nepal and Uganda
The social science component of the OptImms clinical trial is a mixed-methods study exploring how parents and caregivers in Nepal and Uganda perceive changes to childhood immunisation schedules. Carried out alongside the OptImms clinical trial, led by Charlie Firth and in-country collaborators, the study focused on real-world experiences of participants already engaged in vaccine research.
Vaccines have transformed child health globally, averting millions of deaths. But as immunisation schedules evolve to include more vaccines, parents can feel confused or unsure, especially when updates aren’t clearly communicated. This can lead to hesitancy, even among those who strongly support vaccination.
To better understand these concerns, researchers surveyed and interviewed parents whose children took part in the OptImms trial. The trial examined how altering the timing and dosage of the DTP vaccine (against diphtheria, tetanus, and pertussis) might still maintain protection. By combining structured surveys with in-depth interviews, the study uncovered key insights into how trust is built, what information people want, and how vaccine schedule changes are received.
The findings show that practical trust in healthcare workers, previous positive experiences, and clear communication are essential for vaccine acceptance. However, concerns remain around the pace of change, safety, and the need for local evidence. This study offers vital guidance for policymakers and public health teams aiming to maintain high vaccine coverage during times of change, ensuring that progress in childhood immunisation is not only sustained, but strengthened.
Paper outputs forthcoming.